Skip to main content
      #1747 Serious infections ~2× more common in RA-LD, esp RA-ILD. Pulmonary, bacterial, viral & fungal infections all

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #1747 Serious infections ~2× more common in RA-LD, esp RA-ILD. Pulmonary, bacterial, viral & fungal infections all increased, underscoring need for tailored prevention and vaccination. @RheumNow #ACR25 https://t.co/soyzqLk7Vj
      #1746 In large US RA cohort, elevated GDF-15 & pentraxin-3 levels linked to prevalent RA-ILD; high GDF-15 predicted

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      #1746 In large US RA cohort, elevated GDF-15 & pentraxin-3 levels linked to prevalent RA-ILD; high GDF-15 predicted future ILD risk. Other fibrosis-related mediators from IPF or heart failure were not associated, suggesting RA-ILD has distinct pathogenic pathways @RheumNow #ACR25
      #ACR25 Abstr#LB02 Is there a role for JAK-i for the treatment of IgG4-RD? Opel label RCT in China (N=58) showed NO relap

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#LB02 Is there a role for JAK-i for the treatment of IgG4-RD? Opel label RCT in China (N=58) showed NO relapse in Tofacitinib + GC taper vs GC Taper alone (54%). No serious infection. Interesting and a PBO-controlled is warranted @RheumNow https://t.co/dFvAmcGfCT
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      4 months 1 week ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
      STOP RA Cellular & Serologic Predictors

      Dr. Jack Cush discusses abstract 0774, "Longitudinal peripheral blood mult

      Dr. John Cush RheumNow

      4 months 1 week ago
      STOP RA Cellular & Serologic Predictors Dr. Jack Cush discusses abstract 0774, "Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future RA conversion", presented at #ACR25 https://t.co/fS3sFmQJIh https://t.co/V1dVHhUeqF
      Addressing Lupus Nephritis Early
      New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-cli

      Dr. John Cush RheumNow

      4 months 1 week ago
      New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-clinical synovitis. Predicting who will develop RA is difficult, and there is a need for reliable biologic tools. Focusing on high-risk patients could https://t.co/SPOP7f0t7y
      When every option fails, bold moves remain.

      In 5 multi-resistant RA pts, TNFi + JAKi combo brought remission in most w

      Jiha Lee JihaRheum

      4 months 1 week ago
      When every option fails, bold moves remain. In 5 multi-resistant RA pts, TNFi + JAKi combo brought remission in most without major AEs. Not standard, not risk-free, but in young, low-infection-risk pts, it may offer a path forward. @RheumNow #ACR25 Abstract#2272
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in IL-2 as s/c every other day for 12 wks, followed by weekly for another 12 wks vs PBO. Efficacy & T-regs expansion were dose dependent. On to Phase 3 @RheumNow https://t.co/L0rYr5D1R1
      Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA

      30% of pts had relapse, 81% of which were asthma +/- sinona

      Mike Putman EBRheum

      4 months 1 week ago
      Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA 30% of pts had relapse, 81% of which were asthma +/- sinonasal disease Remainder were mostly muscle involved, only a few mononeuritis Mostly as expected; useful epi data for clinic #ACR25 @RheumNow Abstr#1769 https://t.co/IKKolMZJlF
      ×